Multicentric study on malignant pleural mesothelioma in Turkey: Clinicopathologic and survival characteristics of 282 patients

Medical Oncology

Volumn 29, Issue 5, 2012, Pages 3147-3154

  Elkiran, Emin Tamer ^a   Kaplan, Mehmet Ali ^b   Sevinc, Alper ^c   Aksoy, Sercan ^d   Demirci, Umut ^e   Seker, Mesut ^f   Harputluoglu, Hakan ^a   Ozdemir, Nuriye Yildirim ^d   Isik, Feridun ^c   Ulas, Arife ^g   Inanc, Mevlude ^h   Arslan, Ulku Yalcintas ⁱ   Dogu, Gamze Gokoz ^j   Isikdogan, Abdurrahman ^b   Buyukberber, Suleyman ^e  

^a INONU UNIVERSITY   (Turkey)

^b DICLE UNIVERSITY   (Turkey)

^c GAZIANTEP UNIVERSITY   (Turkey)

^d ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^e GAZI UNIVERSITY   (Turkey)

^f DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^g Ankara Oncology Research and Training Hospital   (Turkey)

^h ERCIYES UNIVERSITY   (Turkey)

ⁱ ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^j PAMUKKALE UNIVERSITY   (Turkey)

more..

Author keywords

Asbestos exposure; Front line chemotherapy; Malignant pleural mesothelioma; Multi modality treatment; Prognostic factors

Indexed keywords

ASBESTOS; CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; PEMETREXED; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TURKEY (REPUBLIC); CANCER STAGING; KAPLAN MEIER METHOD; MESOTHELIOMA; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PLEURA TUMOR; RADIOTHERAPY; THORAX SURGERY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; RADIOTHERAPY; RETROSPECTIVE STUDIES; THORACIC SURGICAL PROCEDURES; TREATMENT OUTCOME; TURKEY;

EID: 84880276941     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0276-y     Document Type: Article

References (67)

1. Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol. 2009;39:576-88.
2. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366:397-408.
3. Roggli VL, Sharma A, Butnor KJ, Sporn T, Vollmer RT. Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. Ultrastruct Pathol. 2002;26:55-65.
4. Wagner JC. Mesothelioma and mineral fibers. Cancer. 1986;57:1905-11.
5. Selcuk ZT, Coplu L, Emri S, Kalyoncu AF, Sahin AA, Baris YI. Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases. Chest. 1992;102:790-6.
6. Selcuk ZT, Emri S, Sahin AA, Baris YI, Coplu L, Kalyoncu F, et al. Malignant mesothelioma and erionite exposure. Eur Respir J. 1999;14:480-1.
7. Baris YI. Fibrous zeolite (erionite)-related diseases in Turkey. Am J Ind Med. 1991;19:374-8.
8. Sugarbaker DJ, Norberto JJ. Multimodality management of malignant pleural mesothelioma. Chest. 1998;113:61S-5S.
9. Neumeister W, Gillissen A, Rasche K, Theile A, Muller KM, Schultze-Werninghaus G. Prognosis, staging and therapy of malignant pleural mesothelioma. Med Klin (Munich). 2002;97:459-71.
10. Boutin C, Schlesser M, Frenay C, Astoul P. Malignant pleural mesothelioma. Eur Respir J. 1998;12:972-81.
11. Kaufman AJ, Pass HI. Current concepts in malignant pleural mesothelioma. Expert Rev Anticancer Ther. 2008;8:293-303.
12. Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008;371:1685-94.
13. Antman K, Shemin R, Ryan L, Klegar K, Osteen R, Herman T, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol. 1988;6:147-53.
14. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113:723-31.
15. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest. 1995;108:1122-8.
16. Metintas M, Ozdemir N, Hillerdal G, Ucgun I, Metintas S, Baykul C, et al. Environmental asbestos exposure and malignant pleural mesothelioma. Respir Med. 1999;93:349-55.
17. Yazicioglu S. Pleural calcification associated with exposure to chrysotile asbestos in southeast Turkey. Chest. 1976;70:43-7.
18. Muller KM, Fischer M. Malignant pleural mesotheliomas: an environmental health risk in southeast Turkey. Respiration. 2000;67:608-9.
19. Senyigit A, Bayram H, Babayigit C, Topcu F, Nazaroglu H, Bilici A, et al. Malignant pleural mesothelioma caused by environmental exposure to asbestos in the Southeast of Turkey: CT findings in 117 patients. Respiration. 2000;67:615-22.
20. BarIs YI, Artvinli M, Sahin AA. Environmental mesothelioma in Turkey. Ann NY Acad Sci. 1980;330:423-32.
21. Metintas M, Hillerdal G, Metintas S. Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort. Eur Respir J. 1999;13:523-6.
22. Dumortier P, Gocmen A, Laurent K, Manco A, De Vuyst P. The role of environmental and occupational exposures in Turkish immigrants with fibre-related disease. Eur Respir J. 2001;17:922-7.
23. Baris I, Simonato L, Artvinli M, Pooley F, Saracci R, Skidmore J, et al. Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: a four-year study in the Cappadocian region of Turkey. Int J Cancer. 1987;39:10-7.
24. Emri S, Demir A, Doǧan M. Lung diseases due to environmental exposures to erionite and asbestos in Turkey. Toxicol Lett. 2002;127:251-7.
25. Artvinli M, Baris YI. Environmental fiber-induced pleuro-pulmonary diseases in an Anatolian village: an epidemiologic study. Arch Environ Health. 1982;37:177-81.
26. Sakellariou K, Malamou-Mitsi V, Haritou A, Koumpaniou C, Stachouli C, Dimoliatis ID, et al. Malignant pleural mesothelioma from nonoccupational asbestos exposure in Metsovo (north-west Greece): slow end of an epidemic? Eur Respir J. 1996;9:1206-10.
27. Bianchi C, Giarelli L, Grandi G, Brollo A, Ramani L, Zuch C. Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev. 1997;6:162-6.
28. Baris YI, Bilir N, Artvinli M, Sahin AA, Kalyoncu F, Sebastien P. An epidemiological study in an Anatolian village environmentally exposed to tremolite asbestos. Br J Ind Med. 1988;45:838-40.
29. Metintas S, Metintas M, Ucgun I, Oner U. Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area. Chest. 2002;122:2224-9.
30. Senyigit A, Babayigit C, Gokirmak M, Topcu F, Asan E, Coskunsel M, et al. Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the southeast of Turkey. Respiration. 2000;67:610-4.
31. Schwartz DA. New developments in asbestos-induced pleural disease. Chest. 1991;99:191-8.
32. Brenner J, Sordillo PP, Magill GB, Golbey RB. Malignant mesothelioma of the pleura: review of 123 patients. Cancer. 1982;49:2431-5.
33. Boutin C, Rey F, Gouvernet J, Viallat JR, Astoul P, Ledoray V. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: prognosis and staging. Cancer. 1993;72:394-404.
34. Kurt B, Gülhan M, ApaydIn Z, Ark D. Malignant pleural mesothelioma: a retrospective analysis of 57 cases. ERJ 1997;(Suppl 25):199.
35. Yates DH, Corrin B, Stidolph PN, Browne K. Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax. 1997;52:507-12.
36. Pisani RJ, Colby TV, Williams DE. Malignant mesothelioma of the pleura. Mayo Clin Proc. 1988;63:1234-44.
37. Sovak MA, Aisner SC, Aisner J. Tumors of the pleura and mediastinum. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, editors. Abeloff's clinical oncology, vol. 4. Philadelphia: Churchill Livingstone; 2008. p. 1367-90.
38. Hillerdal G. Malignant mesothelioma 1982: review of 4710 published cases. Br J Dis Chest. 1983;77:321-43.
39. Cugell DW, Kamp DW. Asbestos and the pleura: a review. Chest. 2004;125:1103-17.
40. Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest. 1997;111:106-9.
41. Prakash UB, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin Proc. 1985;60:158-64.
42. Herbert A, Gallagher PJ. Pleural biopsy in the diagnosis of malignant mesothelioma. Thorax. 1982;37:816-21.
43. Whitaker D, Shilkin KB. Diagnosis of pleural malignant mesothelioma in life-a practical approach. J Pathol. 1984;143:147-75.
44. Pistolesi M, Rusthoven J. Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies. Chest. 2004;126:1318-29.
45. Adams VI, Unni KK, Muhm JR, Jett JR, Ilstrup DM, Bernatz PE. Diffuse malignant mesothelioma of pleura. Diagnosis and survival in 92 cases. Cancer. 1986;58:1540-51.
46. Segal A, Whitaker D, Henderson D, Shilkin K. Pathology of mesothelioma. In: Robinson BWS, Chahinian AP, editors. Mesothelioma. London: Martin Dunitz; 2002. p. 143-84.
47. Tammilehto L, Maasilta P, Kostiainen S, Appelqvist P, Holsti LR, Mattson K. Diagnosis and prognostic factors in malignant pleural mesothelioma: a retrospective analysis of sixty-five patients. Respiration. 1992;59:129-35.
48. Butchart EG. Contemporary management of malignant pleural mesothelioma. Oncologist. 1999;4:488-500.
49. Sugarbaker DJ, Jaklitsch MT, Liptay MJ. Mesothelioma and radical multimodality therapy: who benefits? Chest. 1995;107:345S-50S.
50. Tsiouris A, Walesby RK. Malignant pleural mesothelioma: current concepts in treatment. Nat Clin Pract Oncol. 2007;4:344-52.
51. Buduhan G, Menon S, Aye R, Louie B, Mehta V, Vallieres E. Trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2009;88:870-5. (discussion 6).
52. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54-63. (discussion 5).
53. Lucchi M, Chella A, Melfi F, Dini P, Ambrogi M, Fino L, et al. A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2007;31:529-33. (discussion 33-34).
54. Sorensen JB. Current concepts in chemotherapy for malignant pleural mesothelioma. Clin Respir J. 2008;2:74-9.
55. Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer. 2002;38:111-21.
56. Ardizzoni A, Grossi F, Pennucci MC. Systemic drug therapy of malignant pleural mesothelioma. Monaldi Arch Chest Dis. 1998;53:236-40.
57. Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol. 2008;3:756-63.
58. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636-44.
59. Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002;87:491-6.
60. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999;17:25-30.
61. Castagneto B, Zai S, Dongiovanni D, Muzio A, Bretti S, Numico G, et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol. 2005;28:223-6.
62. Favaretto AG, Aversa SM, Paccagnella A, Manzini VP, Palmisano V, Oniga F, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer. 2003;97:2791-7.
63. Lee C, Murray N, Anderson H, Bouttell E. Outcomes with platinum plus gemcitabine or pemetrexed as first-line systemic therapy for malignant pleural mesothelioma in British Columbia: a review of province-wide practice. J Thorac Oncol. 2007;2:606.
64. Metintas M, Metintas S, Ucgun I, Gibbs AR, Harmanci E, Alatas F, et al. Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics. Respir Med. 2001;95:829-35.
65. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16:145-52.
66. Borasio P, Berruti A, Bille A, Lausi P, Levra MG, Giardino R, et al. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg. 2008;33:307-13.
67. Chailleux E, Dabouis G, Pioche D, de Lajartre M, de Lajartre AY, Rembeaux A, et al. Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. Chest. 1988;93:159-62.